MediWound Ltd. reported second quarter 2026 financial results with revenue declining to $3.1 million from $5.7 million in the prior-year period, primarily due to timing of BARDA-funded development revenue. The company recorded a net loss of $7.4 million, or $0.57 per share, compared to a $13.3 million loss previously, driven by non-cash financial income. Cash and equivalents stood at $36 million as of June 30, 2026, with cash burn totaling $20 million in the first half of 2026. MediWound reaffirmed its full-year 2026 revenue guidance of $24–26 million. The company signed a Master Services Agreement with Vericel under its BARDA contract for NexoBrid, expected to contribute revenue in the second half of 2026. EscharEx Phase III VALUE trial enrollment is ongoing, with interim assessment and completion expected by the end of Q1 2027. MediWound Ltd. operates in the biotechnology industry, developing enzymatic therapeutics for tissue repair.